Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 […]
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding – Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose […]
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the Prevention of Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes – Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low […]
Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund – Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced […]
Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European […]
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from […]
(Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research, and teacher of innumerable renowned scientists and academic leaders, helped millions of diabetic patients all over the world with his remarkable work before he passed away on June 18, 2019. Born in Croatia in 1930, […]
TORONTO, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is pleased to appoint Dr. Claude Piché as the Chair of its Board of Directors, replacing Luc Mainville, who has retired from the Board. Additionally, Michael […]
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is pleased to announce that Susan Peers, PhD, has joined the organization as Director of Clinical and Regulatory Affairs. Dr. Peers is a life sciences executive with drug […]
Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer hypoglycemic treatment only once an episode occurs. Zucara is working on the first treatment to prevent hypoglycemia which can kill patients in their sleep. Vancouver, Canada: On World Diabetes Day, Zucara Therapeutics is raising awareness […]